Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minimed GroupMMED +4.16%15 Debt-to-Equity is 0.04 as of Apr. 2026. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 2 warning signs investors should review. Among 705 Medical Devices & Instruments companies, Minimed Group ranks better than 85.39% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Minimed Group's Debt-to-Equity or its related term are showing as below:
MMED'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.04
Current: 0.04
During the past 4 years, the highest Debt-to-Equity Ratio of Minimed Group was 0.04. The lowest was 0.00. And the median was 0.00.
MMED's Debt-to-Equity is ranked better than 85.39% of 705
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs MMED: 0.04
Minimed Group (NAS:MMED) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Minimed Group Debt-to-Equity Related Terms
Minimed Group Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Minimed Group's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MMED vs MMSI, NVST, STVN: Debt-to-Equity Comparison
For the Medical Instruments & Supplies subindustry, Minimed Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minimed Group Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Minimed Group's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Minimed Group (MMED) has a Debt-to-Equity of 0.04 as of Apr. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Minimed Group and its competitors. According to the industry distribution chart, Minimed Group ranks #103 out of 705 companies in the Medical Devices & Instruments industry, placing it in the top 14.6%.
Is Minimed Group's Debt-to-Equity too high?
Minimed Group's current Debt-to-Equity is 0.04. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Minimed Group's value of 0.04 is 82.6% below this industry median. Based on the distribution chart, Minimed Group ranks #103 out of 705 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's Debt-to-Equity compare to MMSI and NVST?
According to the Medical Devices & Instruments industry distribution chart, Minimed Group ranks #103 out of 705 companies for Debt-to-Equity. This places Minimed Group in the top 15% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.23. Minimed Group's value of 0.04 is 82.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 705 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minimed Group's current Debt-to-Equity of 0.04 is 82.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Minimed Group and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minimed Group's current Debt-to-Equity is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current Debt-to-Equity of 0.04. The current Debt-to-Equity is 0.04 and 82.6% below the Medical Devices & Instruments industry median of 0.23. Minimed Group's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Minimed Group (MMED), the current Debt-to-Equity is 0.04 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score
Get the complete analysis for MMED
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MMED has been successfully added to your 
